Jonah Feldman

Tentative approval was given for multiple dose levels of generic enzalutamide tablets for prostate cancer, including 120-mg and 160-mg doses.

Heather J. Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing trials for this rare plasma cell disorder.

Long-term follow-up from IMROZ included findings on MRD dynamics with quadruplet frontline therapy in multiple myeloma.

Results from the SPEARHEAD-1 trial supported FDA approval of the engineered T-cell product for patients as young as 12 years of age.

A scoring tool combining frailty, chronological age, and comorbidities showed distinct outcomes among patients who received allogeneic hematopoietic cell transplant.

At the EHA 2026 Congress, researchers presented novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

A retrospective analysis shows strong outcomes with CAR T-cell therapy in real-world patients with multiple myeloma, Doris K. Hansen, MD, explains.

The FDA set a target date of April 14, 2027 to review ozekibart as targeted treatment for chondrosarcoma.

The phase 3 trial showed benefit with talquetamab/daratumumab with or without pomalidomide as early as the second line in myeloma.

FBEM conditioning in ALL alloHSCT yielded 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

Timothy Hembree, DO, PhD, discusses how patients and physicians have benefited from an AI-supported virtual care system implemented at Moffitt Cancer Center.

A first-in-human trial of the antibody-drug conjugate is planned for later this year.

Tucatinib plus trastuzumab/pertuzumab continued to show benefit in patients with HER2+ breast cancer regardless of distinguishing disease features.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

ctDNA clearance and baseline detectability emerge as prognostic markers in the StrateGIST 1 trial; favorable ORRs seen in early-line cohorts.

The AKT inhibitor ipatasertib resulted in 41% overall response rate when combined with pembrolizumab in head and neck squamous cell carcinoma.

Belantamab plus VRd in newly diagnosed myeloma yields response rates over 85% with dose schedules to manage ocular toxicity.

The FDA granted the NDA for treatment of gastrointestinal stromal tumors with a PDUFA targeted action date of November 30, 2026.

In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel.

The FDA awarded rare pediatric disease and orphan drug designation to the novel small molecule FL118 for osteosarcoma.

A phase 1 trial investigating autologous KMCAR T cells has been initiated in patients with relapsed/refractory multiple myeloma.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.

A combination regimen targeting LAG-3 and PD-1 did not significantly extend progression-free survival in advanced melanoma vs single-agent pembrolizumab.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

The NEO-CYT trial began treating patients with melanoma in the perioperative setting, combining a novel agent with immune checkpoint inhibitor therapy.

Andrzej Jakubowiak, MD, PhD, explains promising results for KRd maintenance and the potential of modifying the posttransplant maintenance paradigm in multiple myeloma.

First-in-class double-loaded patient-derived immunotherapy joins pancreatic cancer and glioblastoma in FDA Fast Track portfolio; phase 1/2 trial now recruiting.

During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.